Tuberculosis (TB) is a major AIDS-related infection. The lengthy and cumbersome therapy currently available to treat TB has contributed to medical nonadherence and the emerging problems of multi-drug resistant (MDR)- and extensive-drug resistant (XDR)-TB. This prolonged therapy reflects the ability of Mycobacterium tuberculosis (Mtb) to persist in the infected host in a nonreplicating state characterized by antibiotic tolerance. The molecular mechanisms underlying Mtb growth restriction are unknown. We and others have shown that the alarmone hyperphosphorylated guanosine ((p)ppGpp) and the regulatory molecule inorganic polyphosphate (poly P) play a role in Mtb survival under growth-limiting conditions. However, the regulatory relationship between (p)ppGpp and poly P and the precise role of this network on Mtb growth restriction and antibiotic tolerance have not been elucidated. In this proposal, we plan to use Mtb recombinant strains conditionally overexpressing RelMtb, the stringent response enzyme responsible for (p)ppGpp synthesis, in order to test the hypothesis that (p)ppGpp is a molecular "brake" responsible for Mtb growth restriction and antibiotic tolerance. Next, using both poly P-deficient and poly P-accumulating Mtb recombinant strains, we will test the hypothesis that poly P regulates Mtb growth restriction and antibiotic tolerance. Finally, we will test the hypothesis that (p)ppGpp and poly P constitute a complex, feedback regulatory loop involving poly P- dependent expression of relMtb and (p)ppGpp-mediated inhibition of poly P hydrolysis. Although poly P is present in all cells, the highly-conserved bacterial enzyme responsible for poly P synthesis in Mtb has not been identified in mammalian cells, thus making it a potentially attractive target for drug development. A small molecule inhibitor of RelMtb would be predicted to lead to reduced Mtb synthesis of (p)ppGpp. Inhibition of this regulatory network may lead to reduced survival of persistent bacilli, with the potential to shorten the duration of TB chemotherapy. In addition to improving medical adherence and reducing the potential for the development of drug resistance, an abbreviated drug regimen to treat active TB could be especially useful in HIV co-infected patients, since drug-drug interactions and immune reconstitution may complicate the concurrent management of both infections.
TB treatment requires at least 6 months of therapy because the germs that cause TB can go dormant when they encounter stress, becoming very difficult to kill with current antibiotics, which kill dividing bacteria. In this proposal, we plan to study some of the important mechanisms that lead TB germs to stop dividing. If we can figure out how TB germs go dormant, we may be able to develop new ways to attack these germs and shorten the time it takes to cure this major AIDS-related infection.
|Heaton, Brook E; Barkan, Daniel; Bongiorno, Paola et al. (2014) Deficiency of double-strand DNA break repair does not impair Mycobacterium tuberculosis virulence in multiple animal models of infection. Infect Immun 82:3177-85|
|Dutta, Noton K; Karakousis, Petros C (2014) PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice. Int J Antimicrob Agents 44:564-6|
|Rifat, Dalin; Karakousis, Petros C (2014) Differential regulation of the two-component regulatory system senX3-regX3 in Mycobacterium tuberculosis. Microbiology 160:1125-33|
|Dutta, Noton K; Illei, Peter B; Jain, Sanjay K et al. (2014) Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice. Am J Pathol 184:2045-55|
|Dutta, Noton K; Bandyopadhyay, Nirmalya; Veeramani, Balaji et al. (2014) Systems biology-based identification of Mycobacterium tuberculosis persistence genes in mouse lungs. MBio 5:|
|Dutta, Noton K; Pinn, Michael L; Karakousis, Petros C (2014) Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Antimicrob Agents Chemother 58:4048-53|
|Dutta, Noton K; Karakousis, Petros C (2014) Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev 78:343-71|
|Skerry, Ciaran; Pinn, Michael L; Bruiners, Natalie et al. (2014) Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 69:2453-7|
|Dutta, Noton K; Alsultan, Abdullah; Gniadek, Thomas J et al. (2013) Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother 57:3910-6|
|Chuang, Yu-Min; Belchis, Deborah A; Karakousis, Petros C (2013) The polyphosphate kinase gene ppk2 is required for mycobacterium tuberculosis inorganic polyphosphate regulation and virulence. MBio 4:e00039-13|
Showing the most recent 10 out of 21 publications